光正眼科(002524) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥186,164,288.40, a decrease of 2.91% compared to ¥191,740,938.17 in the same period last year[3] - The net profit attributable to shareholders was a loss of ¥36,074,792.53, representing a decline of 189.14% from a profit of ¥40,468,120.27 in the previous year[3] - The basic and diluted earnings per share were both -¥0.07, a decrease of 187.50% from ¥0.08 in the same period last year[3] - Operating profit for Q1 2022 was a loss of CNY 35,564,060.30, compared to a profit of CNY 40,504,225.87 in Q1 2021[20] - Net profit for Q1 2022 was a loss of CNY 35,990,985.53, significantly lower than the profit of CNY 40,022,420.82 in the previous year[21] Cash Flow - The net cash flow from operating activities improved to ¥644,464.97, a significant increase of 103.74% compared to a negative cash flow of ¥17,239,416.56 in the same period last year[3] - Cash flow from operating activities generated a net amount of CNY 644,464.97, a recovery from a negative cash flow of CNY 17,239,416.56 in Q1 2021[23] - The net cash flow from financing activities was 15,817,915.33, a significant improvement from -93,890,862.00 in the previous period[24] - The net increase in cash and cash equivalents was 31,139,852.89, contrasting with a decrease of 29,414,699.46 in the previous period[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,798,706,119.43, down 1.96% from ¥1,834,597,029.60 at the end of the previous year[3] - The total liabilities amounted to CNY 1,485,933,923.58, slightly down from CNY 1,487,473,228.26 in the previous period[20] - The total current liabilities decreased to RMB 929,441,630.85 from RMB 980,225,550.04, reflecting a decline of approximately 5.2%[16] Equity - The equity attributable to shareholders decreased by 9.95% to ¥311,850,469.17 from ¥346,292,934.40 at the end of the previous year[3] - The total equity attributable to shareholders of the parent company was CNY 311,850,469.17, down from CNY 346,292,934.40 year-over-year[20] Investment Activities - The company reported a significant decrease in investment income, which fell by 100.75% to -¥543,696.86 from ¥72,398,002.26 in the same period last year[8] - Cash inflow from investment activities was CNY 46,281,394.91, compared to CNY 104,003,054.70 in the previous year[23] - The long-term equity investment increased to RMB 37,440,360.49 from RMB 28,191,302.26, showing a growth of approximately 33%[16] Operational Expenses - Total operating costs for Q1 2022 were CNY 221,611,773.81, down from CNY 224,617,270.22 in the same period last year[19] - The company reported a decrease in sales expenses to CNY 36,664,945.61 from CNY 48,890,770.46 year-over-year, reflecting a reduction of approximately 25%[20] - Research and development expenses decreased to CNY 309,035.23 from CNY 417,703.86, indicating a reduction of about 26%[20] Shareholder Actions - The company completed the repurchase and cancellation of 1,001,800 restricted shares, reducing the total share capital from 516,368,220 shares to 515,366,420 shares[13] - The company reported a total of 3,999,946 shares held in its repurchase special securities account[12] New Developments - Guangzheng Eye Hospital Group invested RMB 10 million in acquiring equity in Suzhou Ear, Nose, and Throat Hospital Co., Ltd.[12] - The company established a new subsidiary, Shanghai Guangzheng New Vision Eye Hospital Investment Co., Ltd., completing its business registration[12] Inventory - Inventory rose to RMB 71,381,704.05 from RMB 53,229,048.92, marking an increase of about 34%[15] Cash and Cash Equivalents - The cash and cash equivalents increased by 205.86% to ¥31,139,852.89, compared to a decrease of ¥29,414,699.46 in the previous year[8] - The ending balance of cash and cash equivalents was 76,161,372.41, slightly down from 78,837,765.50 in the previous period[24] Reporting and Audit - The company did not undergo an audit for the first quarter report[25] - The report was released on April 30, 2022, by the board of directors[25]